CN1646692B - 在肿瘤中差异表达的基因产物及其用途 - Google Patents

在肿瘤中差异表达的基因产物及其用途 Download PDF

Info

Publication number
CN1646692B
CN1646692B CN03807493.1A CN03874931A CN1646692B CN 1646692 B CN1646692 B CN 1646692B CN 03874931 A CN03874931 A CN 03874931A CN 1646692 B CN1646692 B CN 1646692B
Authority
CN
China
Prior art keywords
nucleic acid
tumor
antibody
associated antigen
tpte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN03807493.1A
Other languages
English (en)
Chinese (zh)
Inventor
U·萨因
O·图里斯
M·科斯洛斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ghanimede Pharmaceutical Co ltd
Biontech SE
Original Assignee
Ganymed Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals GmbH filed Critical Ganymed Pharmaceuticals GmbH
Application granted granted Critical
Publication of CN1646692B publication Critical patent/CN1646692B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
CN03807493.1A 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途 Expired - Lifetime CN1646692B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10211088.3 2002-03-13
DE10211088A DE10211088A1 (de) 2002-03-13 2002-03-13 Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
PCT/EP2003/002556 WO2003076631A2 (de) 2002-03-13 2003-03-12 Differentiell in tumoren exprimierte genprodukte und deren verwendung

Publications (1)

Publication Number Publication Date
CN1646692B true CN1646692B (zh) 2015-12-16

Family

ID=27771250

Family Applications (4)

Application Number Title Priority Date Filing Date
CN03807493.1A Expired - Lifetime CN1646692B (zh) 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途
CNA038074931A Granted CN1646692A (zh) 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途
CN201510846314.8A Expired - Lifetime CN105396144B (zh) 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途
CN201310025680.8A Expired - Lifetime CN103251952B (zh) 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CNA038074931A Granted CN1646692A (zh) 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途
CN201510846314.8A Expired - Lifetime CN105396144B (zh) 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途
CN201310025680.8A Expired - Lifetime CN103251952B (zh) 2002-03-13 2003-03-12 在肿瘤中差异表达的基因产物及其用途

Country Status (14)

Country Link
US (8) US7429461B2 (cg-RX-API-DMAC7.html)
EP (18) EP2314611A3 (cg-RX-API-DMAC7.html)
JP (5) JP4963778B2 (cg-RX-API-DMAC7.html)
KR (4) KR20110117735A (cg-RX-API-DMAC7.html)
CN (4) CN1646692B (cg-RX-API-DMAC7.html)
AU (2) AU2003219045B2 (cg-RX-API-DMAC7.html)
CA (3) CA2478413C (cg-RX-API-DMAC7.html)
DE (1) DE10211088A1 (cg-RX-API-DMAC7.html)
ES (3) ES2688186T3 (cg-RX-API-DMAC7.html)
IL (4) IL163900A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04008867A (cg-RX-API-DMAC7.html)
NZ (1) NZ535146A (cg-RX-API-DMAC7.html)
PL (1) PL215160B1 (cg-RX-API-DMAC7.html)
WO (1) WO2003076631A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CN102220423A (zh) * 2002-08-20 2011-10-19 千年药品公司 用于鉴定,评估,预防和治疗子宫颈癌的组合物,试剂盒及方法
DE10341812A1 (de) * 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
AU2015201738B2 (en) * 2003-09-26 2016-10-13 Biontech Ag Identification of tumour-associated cell surface antigens for diagnosis and therapy
DE102004023187A1 (de) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
WO2006073183A1 (ja) * 2005-01-07 2006-07-13 Riken 一塩基多型を用いた炎症性疾患の判定方法
DE102005013846A1 (de) * 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US9492518B2 (en) * 2006-10-04 2016-11-15 Dana-Farber Cancer Institute, Inc. Tumor immunity
EP2108701A1 (en) * 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
EP3572510B1 (en) 2013-11-21 2022-09-21 Repertoire Genesis Incorporation T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis
BR112016019408B1 (pt) 2014-03-21 2020-12-01 Haldor Topsøe A/S módulos de grade livres de gaxetas para suporte de catalisador e um sistema modular disto
LT3230320T (lt) 2014-12-09 2021-01-11 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną
AU2016369519B2 (en) 2015-12-16 2023-04-20 Seattle Project Corp. Neoantigen identification, manufacture, and use
CA3078744A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. Neoantigen identification using hotspots
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
CN110734925B (zh) * 2018-07-20 2023-04-07 上海市免疫学研究所 一种粒细胞或单核细胞标记系统及其标记方法和应用
CN115298328A (zh) * 2020-01-09 2022-11-04 德卡生物科学公司 使用遗传标记、snp和/或indel确定il-10治疗反应性的方法
CA3260041A1 (en) 2022-06-30 2024-01-04 Kmc Kartoffelmelcentralen Amba STARCH-BASED GELATIN REPLACEMENTS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0270056A1 (en) * 1986-12-01 1988-06-08 Northwestern University Human LDH-C 4cDNA sequences encoding antigenic regions
WO2001009345A1 (en) * 1999-07-29 2001-02-08 Helix Research Institute Novel genes encoding protein kinase/protein phosphatase
WO2002010363A2 (en) * 2000-07-28 2002-02-07 Incyte Genomics, Inc. Protein phosphatases

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
WO1997026001A1 (en) * 1996-01-16 1997-07-24 Northwestern University Proteins and peptides for contraceptive vaccines and fertility diagnosis
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
EP1053323A2 (en) * 1998-02-12 2000-11-22 Incyte Pharmaceuticals, Inc. Human receptor proteins
JP3538381B2 (ja) * 1998-05-21 2004-06-14 ダイアデクスアス・インコーポレーテッド 結腸癌を診断し、モニターし、そして病期決定する新規方法
US6440663B1 (en) * 1998-10-05 2002-08-27 Ludwig Institute For Cancer Research Renal cancer associated antigens and uses therefor
WO2001009316A1 (en) * 1999-07-29 2001-02-08 Helix Research Institute Novel genes encoding protein kinase/protein phosphatase
DE19936563A1 (de) * 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumorassoziiertes Antigen
WO2001022920A2 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US7442776B2 (en) 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
WO2001051628A2 (en) * 2000-01-14 2001-07-19 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20020081590A1 (en) * 2000-02-04 2002-06-27 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
AU6802801A (en) * 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
WO2002059271A2 (en) * 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue
AU2002303219A1 (en) 2001-03-30 2002-10-15 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
US20040058341A1 (en) * 2001-07-26 2004-03-25 Y.Tom Tang Protein phosphatases
JP2005536439A (ja) 2001-09-18 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断及び治療のための組成物と方法
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP5565375B2 (ja) 2011-05-12 2014-08-06 三菱電機株式会社 入退室管理装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0270056A1 (en) * 1986-12-01 1988-06-08 Northwestern University Human LDH-C 4cDNA sequences encoding antigenic regions
WO2001009345A1 (en) * 1999-07-29 2001-02-08 Helix Research Institute Novel genes encoding protein kinase/protein phosphatase
WO2002010363A2 (en) * 2000-07-28 2002-02-07 Incyte Genomics, Inc. Protein phosphatases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Charles De Smet et al.Identification of a new mage gene with tumou-specificexpression by representational difference analysis.Cancer research58 4.1998,58(4),743-752. *
CHEN HAIMING ET AL.A testis-specific gene, TPTE,encodesaputativetransmembrane tyrosine phosphatase andmapstothepericentromeric region of human chromosomes21and13,and to chromosomes 15, 22, and Y.HUMAN GENETICS105 5.1999,105(5),399-409. *
Tapan k.Bera et al.Pate agene expressed In prostate cancer mormal prostateand testis Identified by a functional genomic approach.Proceedings of the national academy of sciences of the united states99 5.2002,99(5),3058-3063. *
Valerie martelange et al.Identification on a human sarcoma of two new geneswith tumor-specific expression.Cancer research60 14.2000,60(14),3848-3855. *

Also Published As

Publication number Publication date
AU2003219045A1 (en) 2003-09-22
EP2277902A2 (de) 2011-01-26
US9453260B2 (en) 2016-09-27
ES2559079T3 (es) 2016-02-10
JP2005519608A (ja) 2005-07-07
US20150031025A1 (en) 2015-01-29
EP2311861A3 (de) 2011-07-13
CA3035543A1 (en) 2003-09-18
WO2003076631A2 (de) 2003-09-18
DE10211088A1 (de) 2003-09-25
US20090081214A1 (en) 2009-03-26
US20060013817A1 (en) 2006-01-19
JP5793158B2 (ja) 2015-10-14
JP5756073B2 (ja) 2015-07-29
EP2311862A3 (de) 2011-07-13
EP2277901A3 (de) 2011-05-25
KR101261887B1 (ko) 2013-11-06
KR20120127536A (ko) 2012-11-21
EP2287181A2 (de) 2011-02-23
WO2003076631A3 (de) 2004-06-24
AU2008258158A1 (en) 2009-01-15
EP2287182A3 (de) 2011-06-15
IL244596A0 (en) 2016-04-21
JP4963778B2 (ja) 2012-06-27
JP2013081462A (ja) 2013-05-09
EP2277904A2 (de) 2011-01-26
JP5711711B2 (ja) 2015-05-07
EP2311860A2 (de) 2011-04-20
CN105396144A (zh) 2016-03-16
US20090081215A1 (en) 2009-03-26
EP2277901A2 (de) 2011-01-26
CN103251952B (zh) 2018-11-09
EP2287182B1 (de) 2018-08-29
EP2314612A2 (de) 2011-04-27
MXPA04008867A (es) 2005-06-17
US20170101479A1 (en) 2017-04-13
PL215160B1 (pl) 2013-10-31
EP2277907A3 (de) 2011-05-25
EP2277905A2 (de) 2011-01-26
EP2289910A2 (de) 2011-03-02
US20120014948A1 (en) 2012-01-19
CA2478413A1 (en) 2003-09-18
EP2314611A2 (de) 2011-04-27
CA2813780A1 (en) 2003-09-18
ES2688186T3 (es) 2018-10-31
EP2277904A3 (de) 2011-06-08
AU2003219045B2 (en) 2008-09-18
IL163900A0 (en) 2005-12-18
PL373384A1 (en) 2005-08-22
US8716455B2 (en) 2014-05-06
EP2332973A2 (de) 2011-06-15
EP2314610A2 (de) 2011-04-27
EP2277903A2 (de) 2011-01-26
US9637794B2 (en) 2017-05-02
KR20040095283A (ko) 2004-11-12
EP2277902A3 (de) 2011-05-25
CA2478413C (en) 2020-03-10
ES2685053T3 (es) 2018-10-05
EP2277903A3 (de) 2011-05-25
CN103251952A (zh) 2013-08-21
EP2289910A3 (de) 2011-06-15
CN1646692A (zh) 2005-07-27
KR20110117735A (ko) 2011-10-27
JP2010047597A (ja) 2010-03-04
EP2311861A2 (de) 2011-04-20
EP1483389B1 (de) 2015-11-04
EP2314611A3 (de) 2011-07-20
EP2314610A3 (de) 2011-07-20
EP2311862A2 (de) 2011-04-20
NZ535146A (en) 2006-06-30
EP2277907A2 (de) 2011-01-26
EP2287181A3 (de) 2011-06-15
JP2013172716A (ja) 2013-09-05
EP2311860A3 (de) 2011-07-20
CN105396144B (zh) 2019-08-20
EP2314610B1 (de) 2015-08-26
IL163900A (en) 2015-07-30
US7429461B2 (en) 2008-09-30
EP2277906A3 (de) 2011-05-25
US20160002738A1 (en) 2016-01-07
CA3035543C (en) 2025-09-23
IL235085A (en) 2016-06-30
EP2277905A3 (de) 2011-05-25
EP2289910B1 (de) 2018-08-08
KR20110026529A (ko) 2011-03-15
EP2277906A2 (de) 2011-01-26
EP2311860B1 (de) 2016-09-07
CA2813780C (en) 2019-05-07
EP1483389A2 (de) 2004-12-08
US8551490B2 (en) 2013-10-08
JP2013055938A (ja) 2013-03-28
EP2332973A3 (de) 2011-09-07
EP2314612A3 (de) 2011-08-03
US20130243796A1 (en) 2013-09-19
AU2008258158A8 (en) 2009-01-29
EP2287182A2 (de) 2011-02-23

Similar Documents

Publication Publication Date Title
JP5793158B2 (ja) 腫瘍において示差的に発現される遺伝子産物およびこの使用
JP5711698B2 (ja) 腫瘍において示差的に発現される遺伝子産物およびこの使用
AU2012216265B2 (en) Genetic products differentially expressed in tumors and use thereof
HK1153489A (en) Differential in tumour gene products and use of same
HK1154593A (en) Differential in tumour gene products and use of same
HK1153487A (en) Differential in tumour gene products and use of same
HK1154594A (en) Differential in tumour gene products and use of same
HK1154599A (en) Differential in tumour gene products and use of same
HK1153490A (en) Differential in tumour gene products and use of same
HK1154598A (en) Differential in tumour gene products and use of same

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Germany Mainz

Patentee after: Ghanimede Pharmaceutical Co.,Ltd.

Address before: Germany Mainz

Patentee before: GANYMED PHARMACEUTICALS AG

TR01 Transfer of patent right

Effective date of registration: 20190708

Address after: Germany Mainz

Patentee after: BIONTECH AG

Address before: Germany Mainz

Patentee before: Ghanimede Pharmaceutical Co.,Ltd.

CX01 Expiry of patent term

Granted publication date: 20151216